Management of pulmonary arterial hypertension associated with congenital heart disease

The mechanism of congenital heart diseases (CHD) associated with pulmonary arterial hypertension (PAH) is complicated and poor quality of life (QOL) is usually reported in patients with CHDPAH. Although there have been no effective therapies for CHDPAH, patients’ lifetime can be lengthened, QOL improved and clinical syndrome alleviated using reasonable treatment. Multidisciplinary treatment can improve QOL and prognosis in CHDPAH patients.